Saturday 17 October 2026
Export MDXHF’s income statement to Excel — free account
MedX Health Corp.
MDXHF Healthcare Diagnostics & Research
MedX Health Corp.’s revenue for fiscal 2025 (year ended December 2025) was $338,700.00, down 5.23% from fiscal 2024. In the quarter to June 2026, revenue grew 33.6%, EPS fell 6.06%, free cash flow grew 41.6% and total debt fell 8.75%, each against the same quarter a year earlier.
0.03
0.00
0.00%
Follow MDXHF
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
7.95 | 33.55 | 8.75 | 40.22 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.07) | (22.36) | (3.70) | (29.49) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
13.50 | 39.04 | 12.29 | 48.01 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.06) | (5.23) | (1.56) | (7.84) | |
EV/FCF |
(1.07) | (2.82) | (0.79) | (3.53) | |
Quick Ratio |
0.01 | 0.02 | 0.01 | 0.06 | |
Current Ratio |
0.02 | 0.04 | 0.04 | 0.10 | |
Net Debt/EBITDA |
(2.64) | (3.28) | (1.32) | (4.65) | |
Debt/Assets |
656.36% | 497.19% | 241.50% | 322.96% | |
Debt/Equity |
(0.30) | (0.32) | (0.17) | (0.40) | |
Asset Turnover |
0.77 | 0.79 | 0.59 | 0.48 | |
Operating CF/Net income |
0.70 | 0.66 | 0.53 | 0.55 | |
Capex/Depreciation |
0.00 | (31.21) | (0.14) | (27.98) | |
Interest Coverage |
(3.16) | (2.97) | (2.25) | (2.17) | |
Research and Development Expense of Revenue |
187.72% | 79.55% | 90.32% | 92.67% | |
Selling, General and Administrative Expense of Revenue |
877.31% | 470.14% | 728.23% | 584.42% | |
Intangible Assets out of Total Assets |
0.00 | 177.24 | 155.90 | 85.99 | |
Share Based Compensation of Revenue |
257.19% | 8.95% | 121.77% | 42.67% | |
Graham Net Nets |
(2.41) | (0.54) | (2.42) | (0.50) | |
Graham Number |
0.09 | 0.08 | 0.09 | 0.09 | |
Earnings Yield |
(140.00%) | (34.50%) | (152.00%) | (26.80%) | |
Free Cash Flow Yield |
(158.91%) | (41.33%) | (178.45%) | (33.86%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
(0.02) | (0.02) | (0.02) | (0.02) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.02) | (0.02) | (0.02) | (0.02) | |
Free Cash Flow |
(0.81) | (0.95) | (0.80) | (0.77) | |
Working Capital |
(6.71) | (6.00) | (7.00) | (6.37) | |
Capital Expenditures |
— | (0.36) | 0.00 | (0.26) | |
Net Current Asset Value |
(7.92) | (7.08) | (7.18) | (7.50) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 2.79 | 0.02 | 2.68 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.16 | 0.15 | 0.15 | 0.28 | |
Average Payables |
1.79 | 1.89 | 1.75 | 1.94 | |
Average Inventory |
0.20 | 0.19 | 0.20 | 0.29 | |
Average Assets |
0.53 | 0.49 | 0.57 | 0.78 | |
Average Common Equity |
(7.04) | (6.75) | (6.60) | (6.93) |
Columns are period end dates · fundamentals updated 2 Oct 2026